Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Azur Pharma has completed its acquisition of Pharmelle, a privately held US specialty pharmaceutical business.
Subscribe to our email newsletter
Pharmelle markets branded prescription pharmaceutical products with a focus on the urology and female health markets. Pharmelle has a nationwide sales and marketing infrastructure in the US with 35 sales and marketing professionals. Revenue for 2006 was in excess of $10 million.
Pharmelle's leading products include Urelle and the Natelle brands. Urelle is used for the treatment of symptoms of lower urinary tract infection. Natelle is a range of prescription pre-natal vitamins and mineral supplements.
“This acquisition brings significant benefits to us including nationwide sales and marketing capacity which will be leveraged to market other products that we acquire. Our existing product, Gastrocrom, continues to perform very strongly since it was acquired by Azur in January 2006. The combined business will generate revenues in excess of $20 million for 2007,” commented Seamus Mulligan, Azur Pharma's chairman and CEO.
“We have hit the targets we set for Azur at the start of 2006. We now have the revenue base and infrastructure in the US to accelerate our growth, and add incremental revenue and development programs,” added Seamus Mulligan.